Allianz Asset Management
FOLD

Allianz Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Allianz Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.8M Sell
1,441,683
-45,313
-3% -$650K 0.02% 606
2025
Q4 		$21.2M Buy
1,486,996
+1,097,887
+282% +$10.8M 0.02% 583
2025
Q3 		$3.07M Buy
389,109
+1,333
+0.3% +$9.49K ﹤0.01% 1324
2025
Q2 		$2.22M Buy
387,776
+16,367
+4% +$106K ﹤0.01% 1439
2025
Q1 		$3.03M Sell
371,409
-4,062
-1% -$37.6K ﹤0.01% 1322
2024
Q4 		$3.54M Buy
375,471
+65,201
+21% +$678K ﹤0.01% 1192
2024
Q3 		$3.31M Buy
310,270
+31,159
+11% +$339K ﹤0.01% 1224
2024
Q2 		$2.77M Hold
279,111
– – ﹤0.01% 1191
2024
Q1 		$3.29M Buy
279,111
+16,779
+6% +$215K 0.01% 1019
2023
Q4 		$3.72M Buy
262,332
+7,478
+3% +$84.9K 0.01% 1068
2023
Q3 		$3.1M Sell
254,854
-8,976
-3% -$116K 0.01% 1216
2023
Q2 		$3.31M Buy
263,830
+6,002
+2% +$71.2K 0.01% 1045
2023
Q1 		$2.86M Buy
257,828
+10,121
+4% +$125K 0.01% 1220
2022
Q4 		$3.02M Buy
247,707
+1,433
+0.6% +$16.1K 0.01% 1136
2022
Q3 		$2.57M Buy
+246,274
New +$2.74M 0.01% 1145
2021
Q1 		– Sell
-60,425
Closed -$1.4M – 2212
2020
Q4 		$1.4M Buy
+60,425
New +$1.24M ﹤0.01% 1404
2020
Q2 		– Sell
-44,166
Closed -$408K – 2440
2020
Q1 		$408K Sell
44,166
-102,071
-70% -$970K ﹤0.01% 2129
2019
Q4 		$1.42M Buy
146,237
+107,011
+273% +$980K ﹤0.01% 2036
2019
Q3 		$315K Buy
39,226
+537
+1% +$5.83K ﹤0.01% 2510
2019
Q2 		$483K Sell
38,689
-16,321
-30% -$207K ﹤0.01% 2364
2019
Q1 		$748K Buy
55,010
+23,945
+77% +$292K ﹤0.01% 2192
2018
Q4 		$298K Sell
31,065
-166,856
-84% -$1.83M ﹤0.01% 2412
2018
Q3 		$2.39M Sell
197,921
-499,969
-72% -$6.99M ﹤0.01% 1869
2018
Q2 		$10.9M Sell
697,890
-95,008
-12% -$1.44M 0.01% 1218
2018
Q1 		$11.9M Buy
792,898
+1,638
+0.2% +$24.9K 0.01% 1166
2017
Q4 		$11.4M Buy
791,260
+36,501
+5% +$501K 0.01% 1263
2017
Q3 		$11.4M Buy
+754,759
New +$9.98M 0.01% 1268
2015
Q4 		– Sell
-10,650
Closed -$149K – 2466
2015
Q3 		$149K Sell
10,650
-3,060
-22% -$48K ﹤0.01% 2286
2015
Q2 		$194K Sell
13,710
-10,230
-43% -$123K ﹤0.01% 2321
2015
Q1 		$260K Sell
23,940
-7,760
-24% -$68.4K ﹤0.01% 2149
2014
Q4 		$264K Sell
31,700
-7,490
-19% -$51.4K ﹤0.01% 2138
2014
Q3 		$233K Buy
+39,190
New +$205K ﹤0.01% 2121

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Allianz Asset Management's FOLD Position: Q1 2026 in Review

Allianz Asset Management reduced its Amicus Therapeutics (FOLD) stake by 3% in Q1 2026, selling an estimated $650K and leaving 1,441,683 shares worth $20.8M. The position accounts for 0.02% of the portfolio, ranked #606.

Allianz Asset Management first reported a position in FOLD in Q3 2014 and has held it in 32 quarters since. The position peaked at $21.2M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Allianz Asset Management held 1,441,683 shares of Amicus Therapeutics worth $20.8M as of Q1 2026.
  • Allianz Asset Management sold 45,313 Amicus Therapeutics shares in Q1 2026, an estimated $650K.
  • Amicus Therapeutics made up 0.02% of Allianz Asset Management's portfolio in Q1 2026, its #606 holding.
  • Allianz Asset Management first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 32 quarters since.
  • Allianz Asset Management's Amicus Therapeutics position peaked at $21.2M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.